Structural basis of ligand selectivity and disease mutations in cysteinyl leukotriene receptors.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31811124.
- Also identified by DOI 10.1038/s41467-019-13348-2 and PMC identifier 6897958.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Cysteinyl leukotriene G protein-coupled receptors CysLT<sub>1</sub> and CysLT<sub>2</sub> regulate pro-inflammatory responses associated with allergic disorders. While selective inhibition of CysLT<sub>1</sub>R has been used for treating asthma and associated diseases for over two decades, CysLT<sub>2</sub>R has recently started to emerge as a potential drug target against atopic asthma, brain injury and central nervous system disorders, as well as several types of cancer. Here, we describe four crystal structures of CysLT<sub>2</sub>R in complex with three dual CysLT<sub>1</sub>R/CysLT<sub>2</sub>R antagonists. The reported structures together with the results of comprehensive mutagenesis and computer modeling studies shed light on molecular determinants of CysLTR ligand selectivity and specific effects of disease-related single nucleotide variants.
Medical subject headings
- Mutation
- Receptors, Leukotriene